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ABSTRACT 
 
Purpose: To assess bone mineralization in adolescents with bone tumors at remission 
using quantitative digital ultrasound (QUS) and dual-energy x-ray absorptiometry 
(DEXA), and to compare the bone mineralization values obtained by both methods. 
 
Methods: Patients studied were 36 adolescents (21 boys, 15 girls) who had completed 
treatment of a bone tumor at the University Hospital of the University of Navarra 
(Pamplona, Spain). QUS was performed at the distal metaphysis of the proximal 
phalanxes of the last four fingers of the nondominant hand. A DBM Sonic 1200 
Ultrasound densitometer was used. DEXA measurements were made at the lumbar 
spine (vertebrae L1–L4) using the Hologic QDR 4500 W device. Calcium and vitamin 
D daily intake and grade of physical activity were recorded. 
 
Results: Mean age at bone mineralization determination was 19.11 years. Disease-free 
survival was 4.97 years. Decreased bone mineralization was observed by both methods. 
Bone mineralization absolute values measured by QUS and DEXA were significantly 
correlated. The sensitivity, specificity, diagnostic accuracy, and positive and negative 
predictive values of QUS for predicting osteopenia were 36.4%, 80.0%, 66.7%, 44.4%, 
and 74.1%, respectively. Daily vitamin D intake was below the recommended dietary 
allowances. 
 
Conclusions: Adolescents in remission from bone tumors have low bone mineralization 
determined by DEXA or QUS. 
 
Key Words: Adolescents; Bone mineralization; Bone tumors DEXA; Digital 
ultrasound. 
INTRODUCTION 
 
Improvements in diagnostic methods and intensive treatment protocols in children and 
adolescents with malignancies have significantly increased survival rates, with 
approximately two thirds of these patients reaching adulthood (1). Therefore, the 
possible long-term consequences of treatment and the quality of life in these patients are 
becoming more important. 
 
Many of the adverse effects of cancer treatment are well recognized, such as growth 
retardation, cardiomyopathy, and effects on fertility (2). Osteoporosis and fractures of 
long bones and spine have also been described (3,4). In several studies, decreased bone 
mineralization has been demonstrated in long-term survivors of childhood acute 
lymphoblastic leukemia (2,5,6) and in children with a malignancy at completion of their 
chemotherapy (7-9). However, recent studies are controversial with respect to bone 
mass status in this group of patients (10), and few studies have included patients with 
bone tumors (11,12). 
 
Skeletal manifestations in children and adolescents who have been treated for a 
malignancy are not unexpected, because they have been exposed to multiple agents 
known to impair the acquisition of bone mass (13). Corticosteroids and other 
antineoplastic treatments, such as methotrexate and radiotherapy, have been reported to 
interfere directly with the development of bone mass (5-7,14,15). Nephrotoxic drugs 
such as ifosfamide and cisplatin, which are used for the treatment of bone tumors, may 
lead to abnormalities in renal calcium and vitamin D metabolism. Low levels of bone 
alkaline phosphatase throughout treatment for acute lymphoblastic leukemia have been 
described, suggesting impaired osteoblast differentiation (8,16). Prolonged bedrest, poor 
nutrition, alterations in vitamin D metabolism, growth hormone deficiency, gonadal 
failure, and changes in insulin-like growth factors and their binding proteins might also 
influence bone mineralization in children with malignancies (1,11,17). 
 
In the elderly, bone mass is dependent on both the rate of bone loss and the peak bone 
mass attained during the second and third decades of life. Impaired accumulation of 
skeletal mass during childhood and adolescence might predispose survivors of 
childhood malignancies to osteopenia, osteoporosis, and pathologic fractures later in 
adulthood (5,7). 
  
Dual-energy x-ray absorptiometry (DEXA) is the most widely used technique for bone 
mass measurements. Compared with other methods to determine bone mineralization, 
such as single- and dual-photon absorptiometry and quantitative computed axial 
tomography, DEXA is especially suitable because of its high reproducibility (99%), low 
precision errors (1%), and low radiation doses (1-2 mRem) (18,19). Unfortunately, 
DEXA cannot account for the large changes in body and skeletal size that occur during 
growth, limiting its use in longitudinal studies in children. 
 
Several techniques to measure bone mineralization using ultrasound have been 
developed (20). This method measures the mean speed of sound through bone (Ad-
SOS, m/s). The advantage of this method is that it can give information about the elastic 
quality of bone. This is an important quality since the risk of fractures depends not only 
on bone density but also on the elasticity of bone and its microarchitecture (21). 
Ultrasound has many other advantages compared with DEXA; there is less influence 
from both bone and body size, and it has a high reproducibility, with a low coefficient 
of variation (19). It can be performed in 3 minutes, its costs are low, it is portable, and 
there is no radiation involved, an aspect especially important in children. Soballa et al. 
have shown in osteoporotic women that the predictive value of low bone mineralization 
measured by quantitative digital ultrasound (QUS) in a peripheral bone is 0.93 for 
fracture in the spine or long bone (22). 
 
Until now, there have been few bone mineralization data measured by DEXA in 
children with malignant bone tumors and no such data in these patients using QUS. The 
purpose of this study is to assess bone mineralization in children with bone tumors at 
remission using QUS and DEXA, and to compare the methods. 
 
 
 
METHODS 
 
Patients 
 
We studied 36 adolescents (21 boys, 15 girls; 23 osteosarcomas and 13 Ewing 
sarcomas) of the 75 white patients who were treated and followed for a malignant bone 
tumor at the Department of Pediatrics of the University Hospital, University of Navarra 
(Pamplona, Spain) from 1984 to 2000. We included patients who were in remission, 
who were treated entirely in our hospital, and who did not have a disease that interfered 
with bone metabolism prior to diagnosis. Patients were treated according to the 
international cancer protocols (23-27) (Table 1). Each subject or the parents gave 
written informed consent prior to participation in the study. The study was approved by 
the Ethics Committee of the University Hospital. 
  
 
Methods 
 
Quantitative ultrasound was performed at the distal metaphysis of the proximal 
phalanxes of the last four fingers of the nondominant hand, obtaining the mean bone 
transmission speed of sound. A DBM Sonic 1200 ultrasound densitometer (IGEA, Italy) 
was used. Areal bone mineralization density DEXA measurements (g/cm2) were 
performed at the lumbar spine (vertebrae L1-L4) using an Hologic QDR4500 W 
(Hologic, Waltham, MA, U.S.A.). The coefficient of variation was 0.8% for DEXA and 
0.7% for QUS. The results were expressed quantitatively as standard deviation scores 
(SDS) using previously published reference values (19,28). 
 
Height was determined to the nearest 1 mm using a Harpender stadiometer; weight was 
measured to the nearest 0.1 kg using a digital electronic instrument. Body mass index 
(BMI: weight (kg)/height2 (m2)) was calculated. To calculate the SDS for height, 
weight, and BMI we used the reference values from Cole et al. (29). 
 
Patients’ daily intake of calcium and vitamin D was assessed using a questionnaire (30) 
adapted to our patients by the department’s dietitians. The daily intake values of 
calcium and vitamin D were compared with the daily recommended allowances (31). 
The grade of physical exercise was assessed using a categorical scale modified from 
Kröger et al. (32). 
Statistics 
 
All statistical and data recordings were done on a personal computer using SPSS 
version 10.0 (SPSS, Chicago, IL, U.S.A.). For all the variables studied, we determined 
mean, standard deviation, standard error, confidence interval, and sample size. Results 
are expressed as mean (confidence interval) or median (interquantile range). 
 
A sample of 36 patients was enough to detect with a P value < 0.05 a coefficient of 
correlation (r) of at least 0.33. Coefficients of correlation below 0.33 were not of 
clinical interest. One sample Kolmogorov-Smirnov (Lilliefors) test was used to assess 
the normality of the variables. Paired t tests or Mann-Whitney tests were used according 
to the normality of the variables. All P values were two-tailed, with a level of 
significance less than 0.05. Pearson’s correlation coefficients (r) were calculated to 
study the relationship between quantitative variables. Multivariate normality (P = 0.382) 
(required for Pearson correlation) was assessed by the Small test (with a SPSS Macro) 
(23). A t test was used to test for mean SDS different from 0. To compare the predictive 
power of QUS to detect osteopenia using DEXA as gold standard, the variable was 
dichotomized as osteopenia if the value was below or equal to −1 SDS and normal if 
higher than −1 SDS, according to the WHO classification. QUS sensitivity, specificity, 
positive and negative predictive values and diagnostic accuracy for detecting osteopenia 
were calculated using PEPI 4.0 (24). 
 
 
 
RESULTS 
 
Mean age at diagnosis was 14.27 years (range 12.66–15.89); at bone mineralization 
mean age was 19.41 years (range 17.81–21.02). Mean disease-free survival was 4.97 
years (range 3.60–6.33). Mean height and weight-SDS at evaluation of bone mass were 
−0.08 (range −0.50–0.33) and 0.13 (range −0.35–0.62), respectively. Mean BMI was 
0.42 (range −0.08–0.90) SDS. Weight, height, and BMI did not significantly differ from 
the mean value (29). All patients had developed normal full puberty. Linear growth had 
ceased in all patients. No patient had endocrine abnormalities. Location of primary 
tumors was femur (42%), tibia (36%), flat bones (11%), humerus (8%), and metacarpal 
(3%). Histologic osteosarcoma types were as follows: 14 osteoblastic, 3 chondroblastic, 
3 mixed, 2 telangiectatic, and 1 fibroblastic. Five patients had metastasis at diagnosis. 
All the patients with Ewing sarcoma received local radical radiotherapy and 15 patients 
with osteosarcoma received local intraoperative radiotherapy. Only two patients 
developed renal disease after therapy (loss of magnesium tubulopathy). Total 
cumulative doses of cytostatic agents are shown in Table 2. 
 
Patients with bone tumors had significantly reduced lumbar areal bone mineral density 
at −0.58 (range −0.92 to −0.24) SDS (P = 0.008) compared with references values (19). 
Bone mass assessed by QUS was −0.34 (range −0.85 to −0.17) SDS, lower though not 
significantly (P = 0.18) compared to reference values (28). The absolute values of bone 
mineralization determined by QUS (Ad-SOS; m/s) and DEXA (g/cm2) were 
significantly correlated (n = 36, r = 0.44; P = 0.008). 
  
There were no significant differences in BMI, height, and weight related to sex or type 
of tumor (Table 3). No differences in bone mineralization were found related to the type 
of tumor or type of treatment (Table 4). However, there were significant differences in 
DEXA absolute values (g/cm2) and QUS-SDS values with respect to sex. 
 
Sensitivity of QUS for predicting osteopenia was 36.4% (range 12.8%–66.4%) and 
specificity was 80.0% (range 61.1%–92.3%). Ad-SOS positive predictive value was 
44.4% (range 20.9%–70.8%), and Ad-SOS negative predictive value was 74.1% (range 
63.7% to 82.3%). QUS diagnostic accuracy was 66.7% (range 50.2% to 80.5%). 
 
The mean daily intake of vitamin D, at 0.89 mcg (range 0.70–1.70) was significantly (P 
< 0.001) below the recommended dietary allowances (31). Physical activity seemed to 
be low as well, since 80% of patients performed physical activity less than 2 hours per 
week. None of the patients had bone fractures. No significant correlation between daily 
intake of calcium and vitamin D, physical activity, and bone mineralization was found. 
 
 
DISCUSSION 
 
The patients studied had lower bone mineralization than the reference population 
determined by both DEXA and QUS. It is valuable to evaluate bone mass in children 
and adolescents in or at remission from cancer because it has been speculated that 
decreased bone mineralization in youth means a risk for developing osteoporosis later in 
adulthood. A decrease of 1 SD in bone mineralization has been shown to increase the 
risk for osteoporotic fractures by about 40% to 50% in the perimenopausal population 
(25). If decreased bone mineralization is detected early, factors that might contribute to 
the low value should be recognized and if possible treated. Few patients with bone 
tumors have been included in previous studies of bone mass after childhood cancer 
(11,12). 
 
The cause of this decreased bone mass in children with cancer is probably 
multifactorial, as described in the introduction. We did not investigate all factors 
involved, but we assessed nutritional factors and physical activity in relation with bone 
mineralization. In this study, the growth hormone status of our patients was not directly 
assessed, but their normal height and lack of clinical signs or symptoms of growth 
hormone deficiency make it unlikely that this factor contributes to their low bone mass. 
They also had developed full and normal puberty, so sex hormone abnormalities did not 
seem to be involved in their low bone mass. 
 
Some of the cancer therapies used to treat these types of tumors seem to impair skeletal 
mass, including chemotherapeutic agents such as methotrexate, ifosfamide, and 
doxorubicin (33,34) and local radiotherapy. Methotrexate inhibits DNA synthesis, 
leading to a block in pyrimidine and purine synthesis. Administration of oral 
methotrexate has been previously associated with osteoporosis (3,4). Patients with 
osteosarcoma receive high doses of methotrexate, a drug that interferes with acquisition 
of trabecular bone (35), as do other drugs, such as ifosfamide and bleomycin. 
Ifosfamide and cisplatin can also affect bone metabolism and therefore lead to 
osteopenia (34). 
 
The intake of calcium and vitamin D was below the recommended dietary allowances in 
our patients. Their physical activity was low as well due to the disabilities children 
develop after surgery. Some factors that have a negative influence on bone mass in 
children with bone tumors, such as the disease itself, its treatment, and bedrest, are 
difficult to modify. However, the intake of sufficient amounts of calcium and vitamin D 
can be achieved. It would be important to perform studies to see whether an adequate 
intake of calcium and vitamin D would decrease the risk of osteoporosis and fractures 
later in adulthood (5,7). Children with bone tumors have physical barriers to exercise, 
but patients in remission should be encouraged to participate in physical activities 
because even moderate increases in physical activity are associated with moderate but 
important increases in skeletal mass (36). 
 
The two methods we used both have their advantages and disadvantages. DEXA is very 
precise, but radiation is involved and patients must lie still for 10 to 20 minutes. In 
children with bone tumors, radiation and immobilization can cause problems. With 
QUS, no radiation is involved and children cooperate well. Other important advantages 
are that it is easy, portable, and inexpensive. Alterations in body composition may 
interfere with the transmission of sound, which accounts for the relatively low mean 
speed of sound in obese people and the relatively high mean speed of sound in thin 
people. This illustrates a disadvantage of QUS in obese or thin patients: the 
measurements can be, respectively, under- or overestimated. We do not know if this was 
the case in our patients because we did not directly assess body composition, although 
the patients’ weight and BMI did not significantly differ from the control population. 
Therefore, we do not know if fat mass altered the bone mineralization values that were 
determined using QUS. 
 
The way that body composition affects bone mass in children is controversial. Although 
it has been previously described that overweight children are skeletally advanced (37), 
recent studies have observed that a high proportion of children with distal forearm 
fractures are overweight and have lower bone mass and bone area density (38–46). 
Since physical activity is strongly osteogenic during growth, diminished participation in 
weight-bearing exercise by overweight children could have an adverse effect on bone 
development. However, other authors believe that bone mass in overweight children is 
expected to be high because of the higher intake of food (calcium and vitamin D) and 
the larger weight they must bear, which has a positive influence on bone mass (32,47). 
In our patients both lack of exercise and low intake of food, both during therapy and 
while recovering from surgery, may have had an adverse impact on their bone mass. 
 
The predictive power of ultrasound measurements by means of broadband ultrasound 
attenuation with regard to femoral and spinal fracture risk has been demonstrated 
several times in osteoporotic women (22,39–41). However, most of the studies 
performed to predict fractures using QUS have been done using ultrasound in the 
calcaneus (39–41). QUS does not show good diagnostic accuracy for detecting 
osteopenia in children with cancer, using DEXA as the gold standard. 
 
In conclusion, children in remission from a bone tumor have a lower bone mass than the 
reference population. This was observed by both methods we used. QUS does not seem 
to be a good technique for detecting osteopenia in this group of children. A follow-up 
determination of bone mass should be carried out to identify patients who require 
specific therapeutic interventions to prevent any further decrease in skeletal mass. More 
validation studies are needed to use QUS as a technique to detect osteopenia in children. 
Nutritional follow-up is also necessary to identify patients who may benefit from 
calcium and vitamin D supplements. 
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Table 2. Total cumulative doses of cytostatic agents in patients with osteosarcoma     
and Ewing sarcoma, comparison between both protocols. 
 
Osteosarcoma Ewing sarcoma P value 
Methotrexate (g/m2) 65.55 (37.13; 84.50) 0.23 (0.21; 0.28) <0.001 
Cyclophosphamide (g/m2) 4.25 (2.02; 6.03) 17.73 (13.83; 21.78) <0.001 
Ifosfamide (g/m2) 17.94 (10.87; 32.02) 35.01 (6.78; 52.50) NS 
Doxorubicin (mg/m2) 428.54 (121.58) 470.39 (178.42) NS 
Actinomicin D (mg/m2) 4.30 (3.25; 6.50) 9.67 (3.70) <0.001 
Bleomycin (mg/m2) 95.87 (44.59) 170.80 (63.16) <0.001 
Vincristine (mg/m2) 6.31 (3.85; 9.27) 24.05 (17.93; 35.79) <0.001 
Cisplatin (mg/m2) 465.98 (146.11) —  
NS, not stated. 
 
 
 
 
 
Table 3. Clinical characteristics of the study population (n = 36) 
 Osteosarcoma (n = 23) 
Ewing 
sarcoma      
(n = 13) 
P Females       (n = 21) 
Males        
(n = 15) P 
Age at 
diagnosis 
(years) 
13.73         
(11.63; 15.84) 
15.23         
(12.42; 18.03) 0.828 
13.58         
(10.81; 16.36)
14.77         
(12.65; 16.88) 0.583 
Age at study 
(years) 
19.63         
(17.37; 21.89) 
19.03         
(16.68; 21.37) 0.252 
20.24         
(17.77; 22.71)
18.83         
(16.58; 21.08) 0.658 
Height at 
study (SDS) 
−0.04         
(−0.46; 0.53) 
−0.31         
(−1.17; 0.53) 0.798 
0.25          
(−0.33; 0.82) 
−0.33         
(−0.94; 0.28) 0.246 
Weight at 
study (SDS) 
0.04          
(−0.55; 0.62) 
0.30          
(−0.67; 1.28) 0.795 
0.28          
(−0.48; 1.03) 
0.03          
(−0.66; 0.72) 0.432 
Body mass 
index (SDS) 
0.31          
(0.28; 0.91) 
0.61          
(−0.47; 1.69) 0.469 
0.40          
(−0.48; 1.29) 
0.44          
(−0.26; 1.13) 0.837 
 
 
 
 
Table 4. Comparison of body mass by both methods in both group of patients and by sex 
Body mass 
index 
Osteosarcoma 
(n = 23) 
Ewing Sarcoma 
(n = 13) P 
Females     
(n = 21) 
Males       
(n = 15) P 
QUS                
(Ad-SOS) 
(m/s) 
2044.78 
(2011.03;  
2078.53) 
2048.77 
(1994.45;     
2103.09) 
0.592 
2037.00 
(1984.32; 
2089.68) 
2052.81 
(2020.26;  
2085.36) 
0.387 
QUS                
(Ad-SOS) 
(SDS) 
−0.26 
(0.83; 0.32) 
−0.48 
(−1.60; 0.64) 0.362 
−0.90 
(−1.98; 0.19)
0.06 
(−0.39; 0.50) 0.033 
DEXA   
(g/cm2) 
0.93 
(0.87; 0.99) 
0.97 
(0.89; 1.05) 0.685 
0.98 
(0.93; 1.03) 
0.92 
(0.84; 0.99) 0.009 
DEXA    
(SDS) 
−0.59 
(−1.08; −0.11) 
−0.57 
(−1.07; −0.08) 0.527 
−0.18 
(−0.75; 0.39)
−0.87 
(−1.29; −0.46) 0.891 
 
 
 
 
 
 
